Brand Drug Repackaging Helps Drive Extraordinary Price Increases - GAO
Executive Summary
Repackaged versions of many of the most widely prescribed brand-name drugs appear on a list of those with "extraordinary" price increases between 2000 and 2008, data from a recent analysis by the Government Accountability Office show
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials